TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30938806
Drug: NC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC treatment
Study: 7632811
Drug: rHu-EPO at
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rHu-EPO at an initial dosage of 150 units/kg body weight three times a week, increased to 300 units/kg from the sixth week to the end of the 24-week study
Study: 7632811
Drug: rHu-EPO-untreated patients
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rHu-EPO-untreated patients undergoing alpha-IFN + VMCP combined therapy
Study: 26529118
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg
Study: 11239185
Drug: Neuroprotective drugs
Normalized name: NEUROPROTECTIN D1
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotective drugs
Study: 9239588
Drug: Convection cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection cooling (CC)
Study: 2442957
Drug: Free diet
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free diet with tyrosine (160 mg/kg/24 h)
Study: 30788529
Drug: Baclofen 30
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 30 mg
Study: 30788529
Drug: Baclofen 75
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 75 mg
Study: 20146136
Drug: Dual-task training
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task training (experimental treatment)
Study: 12570122
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (400 mg o.d.)
Study: 12570122
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral therapy (amoxicillin 1 g t.i.d. or clarithromycin 500 mg b.i.d. alone or in combination)
Study: 8946270
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice a day for 12 months
Study: 6126961
Drug: propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (40 mg t.i.d.)
Study: 26881251
Drug: Ranirestat 20
Normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranirestat 20 mg once daily
Study: 24708851
Drug: Complete Decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Decongestive Therapy without manual lymphatic drainage
Study: 24708851
Drug: Complete Decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Decongestive Therapy including manual drainage
Study: 22769857
Drug: Ultracet (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultracet (37.5 mg tramadol/325 mg APAP)
Study: 22769857
Drug: Depain‐X (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depain‐X (65 mg propoxyphene/650 mg APAP)
Study: 20144496
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (1 mL) plus Ringer lactate during arthroscopy
Study: 7675981
Drug: Inositol as
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol as sole therapy for depression
Study: 7148050
Drug: Lidocaine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.0 mg/kg body weight)
Study: 23686414
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination therapy
Study: 16214598
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg to 45 mg)
Study: 20158090
Drug: Glimepiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1 to 4 mg)
Study: 18258791
Drug: Topical esophageal
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical esophageal lidocaine (15 ml)
Study: 18258791
Drug: Baclofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (40 mg orally)
Study: 16636123
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg potassium perchlorate daily
Study: 16636123
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg potassium perchlorate daily
Study: 2867560
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg naproxen sodium initially and then 275 mg naproxen sodium 4-times daily
Study: 2867560
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dextropropoxyphene napsylate initially and then 100 mg dextropropoxyphene napsylate 4-times daily
Study: 24553997
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid (2,000 mg of eicosapentaenoic acid and docosahexaenoic acid)
Study: 24553997
Drug: Gamma-linoleic acid
Normalized name: gamma linoleic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-linoleic acid (borage oil containing 400 mg γ-linoleic acid)
Study: 20533764
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (SR) 2 g/day
Study: 8372340
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg/d)
Study: 20199786
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/d)
Study: 12952834
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with 1.0 mg/kg body weight of recombinant alpha‐Gal A (agalsidase beta, Fabrazyme) for 12 months
Study: 18768350
Drug: Losartan 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 150 mg
Study: 4089261
Drug: 125I permanent
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I permanent implant
Study: 15365074
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy (GEM)
Study: 22446296
Drug: APG101 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG101 (20 mg/kg) administered as infusion over 1 hour to healthy volunteers
Study: 10393400
Drug: n-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: n-acetylcysteine (NAC) in combination with streptokinase
Study: 3593901
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg
Study: 6599496
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AII) infusion at 7.5 ng/kg/min
Study: 23134084
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid liposomes (UAL) at doses of 11, 22, 37, 56, 74, 98, and 130 mg/m(2) administered as a 4-h intravenous infusion
Study: 18311687
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amitriptyline
Study: 9126089
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg paroxetine
Study: 16573705
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg once daily
Study: 12699032
Drug: Sudden within-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sudden within-treatment gain
Study: 10960384
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.2 mg (Group 1)
Study: 10960384
Drug: Intrathecal nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nalbuphine 0.2 mg (Group 2)
Study: 10960384
Drug: Intrathecal nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nalbuphine 0.8 mg (Group 3)
Study: 10960384
Drug: Intrathecal nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nalbuphine 1.6 mg (Group 4)
Study: 24115083
Drug: Intravesical 100
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical 100 U onabotulinumtoxinA injection
Study: 23911756
Drug: β‐blockers (BB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐blockers (BB)
Study: 30919005
Drug: Haloperidol (0.057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.057 mg/kg)
Study: 12091491
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 1,000 mg/d
Study: 24665980
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 750 mg/d
Study: 2403006
Drug: Somatropin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin 0.1 mg/kg (0.27 IU/kg) three times weekly (second year)
Study: 2403006
Drug: Somatropin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin 0.1 mg/kg (0.27 IU/kg) once-daily (second year)
Study: 2403006
Drug: Original treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original treatment regimen (first year) continued (second year)
Study: 25052847
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg)
Study: 9531895
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray applied to the cervix and cervical canal
Study: 12269652
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg
Study: 2879489
Drug: Terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 120 mg
Study: 2084590
Drug: Atracurium 5
Normalized name: cisatracurium 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 5 mg i.v.
Study: 25774017
Drug: Normal medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal medication dispensing (Control Group)
Study: 22251226
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly (QW)
Study: 9190973
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (HRT)
Study: 10383519
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole b.d. (LAC15 group)
Study: 10383519
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole b.d. (LAC30 group)
Study: 1687852
Drug: Theophylline (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (625 mg orally) followed by adenosine infusion (40 micrograms kg‐1 min‐1 for 5 min, 60 micrograms kg‐1 min‐1 for 5 min, and 80 micrograms kg‐1 min‐1 for 30 min)
Study: 1687852
Drug: Theophylline (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (625 mg orally)
Study: 1687852
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion only
Study: 6366805
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg furosemide
Study: 3885701
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg chlorthalidone
Study: 17201610
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both treatments
Study: 27619104
Drug: Yoga practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga practice (1 hour daily for 12 weeks)
Study: 22499962
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin based on the weight-based dosing nomogram
Study: 12527527
Drug: Bupivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (20 ml)
Study: 1871399
Drug: Program of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program of prevention of ill-treatment of very young children
Study: 22176795
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) delivered via contraceptive vaginal ring, 600-800 mcg
Study: 14622078
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nefazodone + CBASP)
Study: 10455342
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment starting at day 6
Study: 8569137
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl and midazolam
Study: 8569137
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of fentanyl and midazolam
Study: 1549538
Drug: Ofloxacin 300
Normalized name: ofloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 300 mg
Study: 23513199
Drug: 10 to
Normalized name: RE-10 Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 16 mm-long hydroxyapatite-coated implants after lateral sinus lifting with 50% organic bovine (Bio-Oss) and 50% autogenous bone (20 patients)
Study: 23513199
Drug: 8 mm
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm implants after crestal sinus lifting with autogenous bone (20 patients)
Study: 23513199
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants
Study: 7917814
Drug: Other preparations
Normalized name: other preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other preparations of lignocaine gel (exact details not specified)
Study: 23446897
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake of 480 mg/d
Study: 22326568
Drug: Open oral
Normalized name: amopen Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open oral challenge test with 200 mL of low-lactose cow's milk
Study: 21212155
Drug: Sorafenib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (800 mg/day) + Gemcitabine (1200 mg/m² on days 1 and 8, every 21 days for a maximum of six cycles)
Study: 16932240
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch (300 microg/day)
Study: 3282032
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance chemotherapy
Study: 22447850
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both medications
Study: 20539246
Drug: Desvenlafaxine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (100-200 mg/d)
Study: 8610868
Drug: Hyaluronidase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase (100 IU = 2 mL) with bupivacaine 0.5% (5.5 mL) and lidocaine 2% (5.5 mL)
Study: 8610868
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 0.5% (5.5 mL) and lidocaine 2% (5.5 mL) without hyaluronidase
Study: 3101549
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 0.2 mg/kg
Study: 3101549
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 0.4 mg/kg
Study: 3101549
Drug: Ketamine 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.1 mg/kg
Study: 27916213
Drug: Esomeprazole (40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40mg once daily)
Study: 27916213
Drug: Esomeprazole (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (dose increased for nonresponders)
Study: 20958958
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment for the elderly
Study: 10831008
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray
Study: 1732426
Drug: Carboplatin 560
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 560 mg/m2 at 4-week intervals
Study: 1732426
Drug: Iproplatin 270
Normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iproplatin 270 mg/m2 at 3-week intervals
Study: 3891946
Drug: Routine phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine phototherapy (after serum bilirubin concentration reached 5 mg/dl)
Study: 30918997
Drug: Arthroscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic treatment
Study: 16278618
Drug: E(2) 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(2) 0.5 mg
Study: 15790044
Drug: Albendazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (800 mg/d for 28 days)
Study: 12358344
Drug: Tobramycin nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin nebuliser solution (TNS)
Study: 15705991
Drug: Inhaled colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled colistin
Study: 15463836
Drug: Tobramycin nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin nebuliser solution (TNS) and Inhaled colistin
Study: 10071997
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 0.1 microg x kg(‐1) x min(‐1) and saline bolus (5 mL)
Study: 10071997
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion and remifentanil bolus (25 microg in 5 mL)
Study: 10071997
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 0.05 microg x kg(‐1) x min(‐1) and remifentanil bolus (12.5 microg in 5 mL)
Study: 10071997
Drug: Variable-rate continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-rate continuous infusion of remifentanil
Study: 6108607
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 100 mg (89.4 mg of ranitidine base) twice daily
Study: 4042390
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily
Study: 6108607
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride (open treatment)
Study: 25913479
Drug: Treatment response
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment response (bone marrow morphology on day 15 and 28)
Study: 15031350
Drug: pH‐neutral low‐GDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH‐neutral low‐GDP solution (Balance)
Study: 23369412
Drug: Ad4-H5-Vtn (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad4-H5-Vtn (all doses combined)
Study: 21452293
Drug: Atacicept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (25 mg, 75 mg, or 150 mg)
Study: 16606972
Drug: Pathologic nodal
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Iodal HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathologic nodal status after chemotherapy
Study: 12488303
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m², 3-weekly cycles, up to 3 cycles)
Study: 15116057
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m²)
Study: 8618283
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no chemotherapy)
Study: 1438493
Drug: Pentobarbital (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (150 mg)
Study: 30430635
Drug: Non-face-to-face group
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-face-to-face group (NFG) using a tablet for the same Go lessons
Study: 26811534
Drug: CELF4 rs1786814
Approvals — FDA: no, EMA: no, PMDA: no
Description: CELF4 rs1786814 GG genotype with anthracycline exposure > 300 mg/m2
Study: 25268802
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg or higher
Study: 22791245
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of 50 mg atenolol
Study: 22791245
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of 50 mg atenolol
Study: 12204875
Drug: Control device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control device (inactive oral appliance)
Study: 10037433
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride per day for 6 months
Study: 1812476
Drug: Euphylong (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphylong (once daily at 2000 hours)
Study: 31893705
Drug: Matrix-based formulation
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-based formulation of the iterative randomized stimulation and averaging (IRSA) method
Study: 373989
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg for 2 weeks)
Study: 31984696
Drug: Symbiotic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic combination (Lactobacillus and Bifidobacterium with fructo‐ and galacto‐oligosaccharides)
Study: 29581669
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) for 4 sessions with 3 day-intervals
Study: 26341262
Drug: 4-day use
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day use of infusion sets
Study: 26341262
Drug: 2-day use
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day use of infusion sets
Study: 20921909
Drug: Glutamic acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamic acid 1.5 grams daily orally in 3 divided doses during the 4-week induction with vincristine (1.5 mg/m² IV weekly)
Study: 19396409
Drug: Trimetazidine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (twice daily)